GET DAILY SIGNALSelectroCore (ECOR) Narrows Losses in Q3 as Margins Hit Record Highs
Key Takeaways
- electroCore reported third quarter 2026 net sales of approximately $9.7 million, up about 12% year over year, though below the roughly $10.9 million consensus revenue estimate.
- Net loss narrowed to $1.3 million, or $0.13 per share, from $3.4 million, or $0.40 per share, a year earlier — beating the consensus estimate of a $0.26 per-share loss.
- Adjusted EBITDA loss improved 67% year over year to $0.7 million, its lowest level on record, with gross margin expanding to 88.5%.
- Full-year 2026 revenue guidance was revised to a range of $39 million to $42 million, while preliminary 2027 guidance calls for 30% to 40% growth and a first quarter of positive Adjusted EBITDA by the end of 2027.
- Cash, cash equivalents, and marketable securities totaled approximately $7.5 million at September 30, 2026.
Why the Quarter Matters
electroCore is a commercial-stage bioelectronic medicine company whose prescription portfolio — led by gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell Fibromyalgia — is increasingly anchored in U.S. Department of Veterans Affairs (VA) sales. The third quarter report matters because it tests whether the company can convert a fast-expanding federal sales channel into structurally better profitability. Coming off back-to-back record revenue quarters, I was watching whether narrower losses and expanding gross margins would continue, and whether management's updated guidance would signal a credible, lower-cost path toward breakeven. The results carry added weight given the company's limited cash position and its stated goal of reaching positive Adjusted EBITDA without a new dilutive equity raise. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Numbers
For the three months ended September 30, 2026, electroCore reported net sales of approximately $9.7 million, a roughly 12% increase from $8.7 million in the prior-year period. Growth was driven primarily by Quell Fibromyalgia and prescription gammaCore sales into the VA channel. Revenue came in below the approximately $10.9 million consensus estimate, while the company's loss per share of $0.13 was narrower than the $0.26 per-share loss analysts had expected.
Gross profit rose to $8.6 million, lifting gross margin to 88.5% from 86.0% a year earlier and 86.5% in the second quarter, reflecting favorable product mix. Operating expenses declined modestly to $10.1 million from $10.4 million a year ago. GAAP net loss was $1.3 million, or $0.13 per share, compared with $3.4 million, or $0.40 per share, in the third quarter of 2025. The quarter benefited from a non-recurring gain of about $0.4 million in other income related to an indemnification settlement.
Adjusted EBITDA loss narrowed to $0.7 million from $2.0 million a year earlier, an improvement of about 67%. Management revised full-year 2026 revenue guidance to $39 million to $42 million, from prior guidance of more than 30% growth, and introduced preliminary 2027 revenue growth guidance of 30% to 40%, with an expectation of achieving its first quarter of positive Adjusted EBITDA by the end of 2027.
Market Reaction and Investor Sentiment
Investor focus around this report centered less on the modest revenue miss and more on the sharp improvement in profitability and the updated pathway toward Adjusted EBITDA breakeven. The record-low loss from operations and 88.5% gross margin reinforced management's message that revenue growth is increasingly translating into bottom-line improvement. Still, sentiment carries a degree of caution: with roughly $7.5 million in cash and marketable securities at quarter-end, questions about funding runway and the pace of cash burn remain central to how the market interprets the results. From what I see, this balance between growth and cost control is worth tracking closely in the quarters ahead.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will likely focus on whether the company can deliver against its revised 2026 revenue range of $39 million to $42 million while continuing to narrow losses. The shift of VA prescription sales through the Lovell distribution agreement is expected to reduce transaction fees and free internal resources for new market development, a dynamic worth monitoring in the fourth quarter and into 2027.
Preliminary 2027 guidance of 30% to 40% revenue growth — and a first quarter of positive Adjusted EBITDA by the end of 2027 — sets a clear benchmark, but achieving it depends on sustained VA account expansion, faster new-representative productivity, and improved patient refill rates. Management has highlighted a national refill rate of 42% year to date, with a stated goal above 70%, making refill trends a key leading indicator.
Other factors to watch include potential label expansion for Quell for chemotherapy-induced peripheral neuropathy, which remains subject to FDA clearance, as well as the company's cash position and any future financing decisions. Progress on these fronts will shape whether electroCore can maintain its improved margin profile while scaling revenue across its federal and commercial channels. I’m watching this closely as the company works toward its profitability targets.
Using AI Tools for Deeper Analysis
In my view, tools like Tickeron’s AI Screener help cut through the noise when reviewing earnings like these. It lets me quickly compare ECOR against peers on fundamentals, patterns, and signals, which adds useful context to the reported results without replacing my own review of the numbers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ECOR in downward trend: price dove below 50-day moving average on October 08, 2026
ECOR moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend. In 42 of 45 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ECOR as a result. In 74 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The Moving Average Convergence Divergence Histogram (MACD) for ECOR turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 38 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
The 10-day moving average for ECOR crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ECOR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for ECOR entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ECOR's RSI Indicator exited the oversold zone, 19 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +13.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where ECOR advanced for three days, in 240 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
ECOR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ECOR's P/B Ratio (-23.364) is slightly lower than the industry average of (4.170). P/E Ratio (-4.382) is within average values for comparable stocks, (1.500). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (2.571) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. ECOR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 72 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ECOR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of non-invasive neuromodulation therapies
Industry MedicalNursingServices
Advertisement